@alexsfelixecho Agree! The early data encouraging, may eliminate mid cavitary gradient, improve wall stress and diastolic function https://t.co/MenINTRPUy
So far, Altmetric has seen
261 X posts from 231 X users, with an upper bound of 1,002,780 followers.
6,961 followers
4,172 followers
7a) The dose-finding #DBRCT Ph 2 #MAVERICK_HCM in symptomatic pts w/non-obstructive #HCM(34) randomized 1:1:1 to placebo or #mavacanten 200 or 500 mg, then followed 16 weeks. See 🔓https://t.co/kUWqc9soDd.
4,172 followers
49) In Ph 2 #MAVERICK_HCM trial in non-obstructive #HCM, #Mavacamten showed a reduction in #NTproBNP & #TnI. But only 1/3 of patients with a more severe phenotype (elevated Troponin I or E/e’) improved in terms of NYHA class and pVO2. See 🔓 https://t.c
4,172 followers
57) #Mavacamten was also evaluated for safety and dose finding in non-obstructive HCM (#nHCM) in the phase II #MAVERICK_HCM trial. See 👉https://t.co/kUWqc9sWsL. https://t.co/u8I7LPnmGP